A clinical prediction model for outcome and therapy delivery in transplant-ineligible patients with myeloma (UK Myeloma Research Alliance Risk Profile): a development and validation studyGordon Cook, Graham Jackson, Kara‐Louise Royle et al.|The Lancet Haematology|2019Cited by 109
Risk of COVID-19 death in cancer patients: an analysis from Guy’s Cancer Centre and King’s College Hospital in LondonBeth Russell, Kavita Raj, Charlotte Moss et al.|British Journal of Cancer|2021Cited by 59
Safety, tolerability, and pharmacokinetics of lisaftoclax (APG-2575)-based therapy in patients with chronic lymphocytic leukemia: Phase 1b/2 studyMatthew S. Davids, Yifan Zhai, Alexander G. Myasnikov et al.|Med|2025Cited by 6
Molecular Treatment Stratification for Newly Diagnosed High-Risk Myeloma, Including Plasma Cell Leukemia - Feasibility Results of the Ukmra Optimum: MUK9 Trial (NCT03188172)Matthew Jenner, Martin Kaiser, Amy L. Sherborne et al.|Blood|2019Cited by 2
Abstract S12-03: Clinical and demographic characteristics associated with shorter time to COVID-19 deathMaria J. Monroy‐Iglesias, Saoirse Dolly, Anne Rigg et al.|Clinical Cancer Research|2021Cited by 0